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Background. Glucosamine may be eﬀective in treating and possibly slowing the progression of Osteoarthritis (OA). It is believed
Glucosamine supplements may help to stop cartilage breakdown, build cartilage and decrease swelling. Objective. The objective
of this study was glucosamine sulfate versus combination of glucosamine sulfate and Non-Steroidal anti-inﬂammatory drugs
(NSAID) in mild to moderate knee osteoarthritis. Methods. Subjects were randomly recruited from Rheumatology outpatient
department after a diagnosis of mild or moderate Osteoarthritis. Study tools like patient data collection form, Western Ontario
McMaster Universities Arthritis index (WOMAC) of Osteoarthritis questionnaires and Visual Analog Scale (VAS) were used.
Results. After 12 weeks, WOMAC total score the result showed that the signiﬁcant mean diﬀerence between the group A and
Group B treatment (P<0.01), with a combination of GS and NSAIDs reducing VAS pain scores. Thus, it is found that Group
B treatments over 4 and 12 weeks produced improved WOMAC and VAS grades. Conclusions. Study results may suggest that the
Glucosamine Sulfate has a carryover eﬀect like Disease modifying agents. Long-term treatment of Glucosamine Sulfate may reduce
the dependence of NSAIDs usage and delay the disease progression. Thereby we can reduce the NSAIDs side eﬀects and improve
the patient’s quality of life.
1.Introduction
Pharmacological treatment of osteoarthritis can be di-
vided into two groups: symptom-modifying and disease-
modifying drugs [1]. Symptom-modifying drugs are at
present the prescription of choice for patient with os-
teoarthritis, forexample, NSAIDs. However, theyare alsothe
case of serious side eﬀects [2, 3]. Disease-modifying agents
are not yet available in usual care. Of most biological agents,
glucosamine sulfate seems to be most promising [4, 5].
Glucosamine, which occurs naturally in the body, plays a key
role in the construction of cartilage (the tough connective
tissue that cushions the joints). Glucosamine is the most
fundamental building block required for biosynthesis of the
classes of compounds including glycolipids, glycoproteins,
hyaluronate, and proteoglycans [6, 7]. As a component
of these macromolecules, glucosamine has a role in the
synthesis of cell membrane, lining, collagen, osteoid, and
bone matrix. Glucosamine is also required for the formation
of lubricants and protective agents such as mucin and
mucous secretion [8, 9].
Objectives. T h eo b j e c t i v e so ft h i ss t u d ya r et od e t e r m i n e
the eﬀectiveness of Glucosamine sulfate in reducing joint
pain in mild to moderate knee OA, to assess the eﬀec-
tiveness of glucosamine sulfate in improving joint physical
function in mild to moderate knee OA, and to ensure the
therapeutic eﬃcacy and safety of glucosamine sulfate as
a disease-modifying agent in osteoarthritis compared with
a combination of glucosamine sulfate and nonsteroidal anti-
inﬂammatory drug in mild to moderate knee OA.2 The Scientiﬁc World Journal
2.MaterialsandMethods
2.1. Study Population. This study includes male and female
patients in the age group more than 20 years. The subjects
who were able to provide written informed consent have
been included in the study. Rheumatoid arthritis patients
and the patients with joint replacement in knees were
excluded. Also, pregnant and lactating women as well as
the patients having a history of chronic infection such as
hepatitis and COPD were excluded [10]. Study subjects were
randomly recruited from Rheumatology Outpatient Depart-
ment after a diagnosis of mild or moderate osteoarthritis. In
total, 143 patients were interviewed, 100 qualiﬁed, and 82
completed the study. Group A consists of 43 patients and
groupBconsistsof39patients.GroupApatientsweretreated
with glucosamine sulfate (GS) 500mg t.i.d and reviewed on
every 30 days once for 3 months. Group B patients were
treated with glucosamine sulfate 500mg t.i.d along with any
one of the conventional NSAIDs (Ibuprofen or Piroxicam)
and reviewed on every 30 days once for 3 months.
2.2. Statistical Methods. Documented datas were entered
into SPSS.PC version 8 [11]. Within the group, variables
were compared with paired t-test. Between the groups,
variables were compared with independent t-test. Statistical
signiﬁcance was taken at the 95% level (P<0.05). Results
were expressed as mean ± standard deviation [12].
2.3. Source of Data. Baseline demographic information
like sex, age, comorbidities, duration of osteoarthritis
and medication history were collected from patient’s case
sheet, patient’s medication chart, and direct interview [13].
Study tools like patient data collection form, Western
Ontario McMaster Universities Arthritis index (WOMAC)
Osteoarthritis questionnaires [14], and visual analog scale
(VAS) were used [15].
2.4. Outcome Measures
2.4.1. Primary Eﬃcacy Variables. The western Ontario and
McMaster universities (WOMAC) osteoarthritis index is a
disease-speciﬁc self-administered health status measure that
is widely accepted as reﬂective of Osteoarthritis disease
activity [16]. The original index consists of 24 Questions
(5 pain, 2 stiﬀness and 17 physical function). Individual
question response is assigned a score of between 0 (none)
to 4 (extreme) and summed to form a score ranging from 0
(best) to 96 (worst). There are three sections to the WOMAC
score; section A deals with the amount of pain (5 questions),
section B address the amount of joint stiﬀness (2 questions),
sectionCaddress aspectsofphysicalfunction(17questions).
2.4.2. Secondary Eﬃcacy Variables. VAS-visual analog scale
score uses a 100mm linear measure of pain status with 0
representing no pain and 100 being unbearable pain [17].
Patients marked on the linear scale the relevant amount of
pain they were experiencing, and the value was noted.
3. Results and Discussion
In total, 143 patients were interviewed. 100 subjects with
OA of the knee were randomized and divided into two
groups. All subjects received trial medication immediately
after randomization [18]. 18 subjects were dropped out form
this study because they were lost to followup and refused
further therapy [19], 8 subjects due to poor compliance
(3GS, 5GS + NSAID), 6 due to gastrointestinal upset (GS +
NSAID), and 4 due to inadequate pain control (GS) [20].
Finally, 82 subjects completed the study: group A (GS, n =
4 3 ) ,g r o u pB( G S+N S A I D ,n = 39). Among the study
subjects, the mean age of the female subjects (47.96 ± 5.09
and 48.95 ± 8.94) was lower than the male subjects in groups
AandB.ThisresultindicatesfemalesareaﬀectedbykneeOA
much earlier than male [21]. Out of 82 subjects studied, the
percentageoffemalesubjectswasgreaterthanthepercentage
of male subjects, that is, 60.46% and 53.84%, respectively
in group A and group B. This result showed that females
are more prevalent to knee OA [22] .T h es u b j e c t sw i t ht h e
age groups of 41–50 years and 51–60 years were the highest
in number by 21 (48.83%) and 19 (44.18%) in group A
and 14 (35.89%) in group B. 2 (4.65%) subjects in the age
group of less than 40 years were noted in group A but 0% in
groupBwerereportedduringthestudyperiod.Amongthese
patients, 10 (23.25%), 5 (12.82%) were aﬀected by left knee
OA, 11 (25.58%), 12 (30.76%) were aﬀected by right knee
OA, and 22 (51.62%), 22 (56.41%) were aﬀected by bilateral
knee OA in groups A and B. This result clearly indicates the
most of the subjects aﬀected by bilateral knee OA [23].
The mean body mass index (BMI) ratio of subjects was
noted under the overweight category [24]. In group A, 25.6
was noted in both male and female. In group B, 25.83 and
26.48 were noted in males and females, respectively. This
result showed that the overweight people are more promptly
aﬀe c t e db yk n e eO A[ 25].
3.1. Primary Eﬃcacy Variables Data. This data revealed that
the mean WOMAC pain score of group A was 16.83 ± 1.68
on 0 week (n = 43) and 17.5 ± 0.93 after 4 weeks. The mean
diﬀerence was not statistically signiﬁcant. But, after 4 weeks,
the mean WOMAC pain score was 10.58 ± 0.58 with the
meandiﬀerenceof6.25 ±1.83.Thismeanscoredecreasewas
statisticallyhighlysigniﬁcant(P<0.01).ThemeanWOMAC
pain score of group B was 18.17 ± 1.84 on 0 week (n = 39)
and 13.3 ± 2.56 after 4 weeks.
The diﬀerence was statistically signiﬁcant (P<0.01).
After 12 weeks, the mean WOMAC pain score was 5.20 ±
1.12 with the mean diﬀerence of 12.97 ± 2.15 (Table 2). This
result revealed that the score decrease was statistically highly
signiﬁcant (P<0.01) [26].
Betweenthegroupsanalysis,theresultsshowedthemean
diﬀerencewas4.20(95%conﬁdentinterval(CI)3.33to5.03)
on ﬁrst review (P<0.01). The men diﬀerence was 5.37
(95% conﬁdent interval 4.97 to 5.78) on last review (after
12 weeks) see Table 1. These results revealed the signiﬁcant
mean diﬀerence between group A and group B (P<0.01)
[27].The Scientiﬁc World Journal 3
Table 1: Comparison of WOMAC pain mean score between group
A and group B.
Review Mean
diﬀerence
95% conﬁdence interval
t-value of the diﬀerence
Lower Upper
0 week 1.3423 2.1234 0.5611 3.421∗
4 weeks 4.2039 3.3288 5.079 9.664∗
8 weeks 4.3703 3.7113 5.0293 13.204∗
12 weeks 5.3763 4.9724 5.7801 26.669∗
∗P<0.01.
Table 2: Comparison of WOMAC stiﬀness mean score between
g r o u pAa n dg r o u pB .
Review Mean
diﬀerence
95% conﬁdence interval
t-value of the diﬀerence
Lower Upper
0 week 0.2689 0.6406 0.0960 1.444NS
4 weeks 1.3584 1.1049 1.1611 10.686∗
8 weeks 1.6971 1.1414 1.9792 12.015∗
12 weeks 2.2308 2.2130 2.4402 21.333∗
∗P<0.01, NS: Not signiﬁcant.
The mean WOMAC stiﬀness score of group A was 6.37 ±
0.69 on 0 week (n = 43) and 6.25 ± 0.49 after 4 weeks. The
decrease was not statistically signiﬁcant.
But,after12weeks,themeanWOMACstiﬀnessscorewas
4.00 ± 0.30 with the mean diﬀerence of 2.37 ± 0.69. This
result revealed that the mean score decrease was statistically
signiﬁcant (P<0.01). The mean WOMAC stiﬀness score of
group B was 6.64 ± 0.95 on 0 week (n = 39) and 4.89 ±
0.64 after 4 weeks. The decrease was statistically signiﬁcant
(P<0.01). But, after 12 weeks, the mean WOMAC stiﬀness
scorewas1.76 ±0.58withthemeandiﬀerenceof4.87 ±0.62.
This result revealed that the score decrease was statistically
highly signiﬁcant (P<0.01).
Between the groups analysis, results showed the mean
diﬀerence was 1.35 (95% conﬁdent interval 1.10 to 1.61)
on ﬁrst review (P<0.01). The mean diﬀerence was 2.23
(95% conﬁdent interval 2.02 to 2.44) after 12 weeks, see
Table 2.Theseresultsrevealedthesigniﬁcantmeandiﬀerence
between group A and group B (P<0.01) [28].
The mean WOMAC function score of group A was 24.51
± 2.17 on 0 week (n = 43) and 29.25 ± 3.43 after 4 weeks.
The mean decrease was not statistically signiﬁcant. But, after
12 weeks, the mean WOMAC function score was 16.02 ±
1.14 with the mean diﬀerence of 8.48 ± 2.93. This result
revealed that the mean score decrease was statistically highly
signiﬁcant (P<0.0 1 ) .T h em e a nW O M A Cf u n c t i o ns c o r eo f
group B was 25.58 ± 2.37 on 0 week (n = 39) and 21.69
± 2.36 after 4 weeks. The mean decrease was statistically
signiﬁcant (P<0.01). After 12 weeks, the mean WOMAC
function score was 7.82 ± 1.86 with the mean diﬀerence
of 17.76 ± 2.59. This result revealed that the mean score
decrease was statistically highly signiﬁcant (P<0.01).
Table 3: Comparison of WOMAC function mean score between
g r o u pAa n dg r o u pB .
Review Mean
diﬀerence
95% conﬁdence interval
t-value of the diﬀerence
Lower Upper
0 week 1.0781 2.0817 0.0745 2.139NS
4 weeks 7.5635 1.8305 16.9575 1.624NS
8 weeks 5.8968 5.0456 6.7481 13.797∗
12 weeks 8.2027 7.5122 8.8933 23.745∗
∗P<0.01, NS: Not signiﬁcant.
Table 4:ComparisonsofWOMACtotalmeanscorebetween group
A and group B.
Review Mean
diﬀerence
95% conﬁdence interval
t-value of the diﬀerence
Lower Upper
0 week 3.1181 4.7903 1.4458 3.712∗
4 weeks 8.452 6.9091 9.9949 10.975∗
8 weeks 11.7847 10.4513 13.1181 17.603∗
12 weeks 15.7865 14.681 16.8921 18.659∗
∗P<0.01.
Between the groups analysis, results showed the mean
diﬀerence was 7.56 (95% conﬁdent interval −1.83 to 16.95)
on ﬁrst review (P<0.01). The men diﬀerence was 8.20 (95%
conﬁdent interval 7.51 to 8.87) after 12 weeks, see Table 3.
These results revealed the signiﬁcant diﬀerence between the
g r o u pAa n dg r o u pB( P<0.01) [29].
The mean WOMAC total score of group A was 47.65 ±
3.69 on 0 week (n = 43) and 48.09 ± 2.23 after 4weeks.
No change was observed by 4 weeks. But, after 12 weeks, the
mean WOMAC total score was 30.58 ± 1.41 with the mean
diﬀerence of 17.06 ± 4.54. This result revealed that the mean
score decrease was statistically highly signiﬁcant (P<0.01).
The mean WOMAC total score of group B was 50.76 ± 3.88
on 0 week (n = 39) and 39.64 ± 4.31 after 4 weeks. The
decrease was statistically signiﬁcant (P<0.01). But, after 12
weeks, the mean WOMAC total score was 14.79 ± 3.16 with
the mean diﬀerence of 35.97 ± 4.24. This result revealed that
the mean score decrease was statistically highly signiﬁcant
(P<0.01).
Between the groups analysis, results showed the mean
diﬀerence was 8.45 (95% conﬁdent interval 6.90 to 9.99)
on ﬁrst review (P<0.01). The mean diﬀerence was 15.78
(95% conﬁdent interval 14.68 to 16.89) on last review (after
12 weeks), see Table 4. These results revealed the signiﬁcant
diﬀerence between group A and group B (P<0.01) [30].
3.2. Secondary Eﬃcacy Variables Data. Analysis of Group A
(n = 43) showed that the mean VAS pain score was 8.65 ±
0.74 on 0 week and 8.7 ± 0.40 on after 4 weeks. The mean
diﬀerence was not statistically signiﬁcant in ﬁrst review. But
after 12 weeks the mean VAS pain score was 6.39 ± 0.72
with the mean diﬀerence of 2.25 ± 0.84. This result clearly4 The Scientiﬁc World Journal
Table 5: Comparisons of VAS Pain mean score between group A
and group B.
Review Mean
diﬀerence
95% Conﬁdence Interval
t-value of the diﬀerence
Lower Upper
0w e e k −0.5668 0.8682 0.2654 3.743∗
4 weeks 0.7897 0.5625 1.017 6.936∗
8 weeks 0.8927 0.5841 1.02013 5.764∗
12 weeks 1.1261 0.8369 1.4127 7.824∗
∗P<0.01.
indicates the mean decrease in pain score was statistically
signiﬁcant (P<0.01).
Analysis of Group B (n = 39) showed that the mean VAS
pain score was 9.21 ± 0.62 on 0 week and 7.91 ± 0.62 on
after 4 weeks. The diﬀerence was not statistically signiﬁcant
in ﬁrst review. But, after 12 weeks, the mean VAS pain score
was 5.26 ± 0.57 with the mean diﬀerence of 3.94 ± 0.62. This
result clearly indicates the mean decrease in pain score was
statistically signiﬁcant (P<0.01).
Between the groups analysis, results showed the mean
diﬀerence was 0.79cm (95% conﬁdent interval 0.56 to 1.01)
on ﬁrst review (P<0.01). The mean diﬀerence was 1.12
(95% conﬁdence interval 0.84 to 1.41) after 12 weeks, see
Table 5.
This result revealed the signiﬁcant mean diﬀerence
b e t w e e ng r o u pAa n dg r o u pBt r e a t m e n t( P<0.01), with
a combination of GS and NSAIDs reducing VAS pain scores.
4. Conclusions
This study demonstrates the eﬃcacy of glucosamine sulfate
(GS) compared with a combination of glucosamine sul-
fate and nonsteroidal anti-Inﬂammatory drugs (NSAIDs)
in Mild to Moderate Knee osteoarthritis Patients based
on the comparison of WOMAC Pain, stiﬀness, physical
function, total score, and VAS pain score. The results
from the ﬁrst review revealed that the combination of GS
with NSAIDs showed better improvement in pain, stiﬀness
and physical function compared with glucosamine sulfate
alone group. After the ﬁnal review, results revealed that
the GS group also has signiﬁcant improvement in pain,
stiﬀness and physical function but lesser compared with
GS and NSAIDs group. This study results may suggest
that the Glucosamine Sulfate has a carryover eﬀect like
disease modifying agent. However, long-term treatment of
glucosamine sulfate may reduce the dependence of NSAID
usage and delay the disease progression. Thereby, we can
reduce the NSAIDs side eﬀects and improve the patient’s
quality of life.
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